Clinical trials: Semaglutide, completed
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe).
- Trial name
- PIONEER 12 (NCT04017832)
- Testing
- Oral semaglutide, Sitagliptin
- Where
- 93 sites in Algeria, Brazil and 7 more
- Volunteers
- 1,441 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes
Semaglutide 2.4 mg in Patients With Poor Weight-loss
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery.
- Conditions
- Obesity, Diabetes, Metabolic Syndrome
- Trial name
- BARI-STEP (NCT05073835)
- Testing
- Semaglutide 3 mg
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University College, London
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.
- Trial name
- SURPASS-2 (NCT03987919)
- Testing
- Tirzepatide, Semaglutide
- Where
- 127 sites in United States, Argentina and 7 more
- Volunteers
- 1,879 people
- Sponsor
- Eli Lilly and Company
Diabetes (DM), Type 2 Diabetes
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus).
- Conditions
- Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)
- Trial name
- SEMA-CKM (NCT07424430)
- Testing
- Semaglutide (SEMA)
- Where
- Canada
- Volunteers
- 3,392 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Chronic Kidney Disease, Type 2 Diabetes
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Obesity
- Trial name
- NCT06131372
- Testing
- Cagrilintide, Semaglutide
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 626 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections.
- Trial name
- NCT04940078
- Testing
- Cagrilintide, semaglutide, Cagrilintide and semaglutide
- Where
- 2 sites in Canada, Denmark
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months).
- Trial name
- NCT06269120
- Testing
- Oral Semaglutide
- Where
- 19 sites in Hungary
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD…
- Trial name
- SUSTAIN™ 2 (NCT01930188)
- Testing
- semaglutide, sitagliptin
- Where
- 141 sites in Argentina, Bulgaria and 16 more
- Volunteers
- 1,231 people
- Sponsor
- Novo Nordisk A/S
Obesity, Aging
Semaglutide Use in Elderly Obese Patients
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly…
- Trial name
- NCT05302596
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH)
Combined Active Treatment in Type 2 Diabetes With NASH
The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the…
- Conditions
- Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- COMBAT_T2_NASH (NCT04639414)
- Testing
- Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
- Where
- 26 sites in Austria, Germany
- Volunteers
- 192 people
- Sponsor
- German Diabetes Center
Metabolism and Nutrition Disorders, Overweight or Obesity
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body.
- Trial name
- NCT03574584
- Testing
- NNC0165-1562, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability of ascending single s.c. doses of NNC 0113-0217 in healthy male subjects, aiming at establishing the Maximum Tolerated Dose (MTD)
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT03144271
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity &Amp; Overweight
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
This clinical study investigates how blocking the hunger-related ghrelin receptor affects appetite and metabolism in individuals with obesity who are treated with semaglutide (a GLP-1 receptor agonist).
- Trial name
- SILENCED (NCT07171723)
- Testing
- Liver-Expressed Antimicrobial Peptide 2 (LEAP2)
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE GERMANY (NCT04261933)
- Testing
- semaglutide
- Where
- 95 sites in Germany
- Volunteers
- 789 people
- Sponsor
- Novo Nordisk A/S
Epicardial Fat
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R).
- Trial name
- NCT04200625
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Miami
Obesity
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in…
- Trial name
- NCT06771115
- Testing
- VTX3232 30 mg, VTX3232 30 mg in combination with semaglutide
- Where
- 14 sites in United States
- Volunteers
- 175 people
- Sponsor
- Zomagen Biosciences Ltd.
PCOS, Semaglutide
The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity
The purpose of the study is to explore the effects of GLP-1 receptor agonist (GLP-1 RA) semaglutide on modulation of taste sensitivity, tongue tissue transcriptome, modulation of neural response in central reward processing…
- Conditions
- PCOS, Semaglutide, Taste, Altered, Tongue Tissue Transcriptome
- Trial name
- NCT04263415
- Testing
- Semaglutide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Diabetes Mellitus, Type 2
A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
This study will look at a new medicine, called IcoSema, for treatment of type 2 diabetes. IcoSema is a combination of a new insulin, called insulin icodec, and a GLP-1 receptor analogue, called semaglutide.
- Trial name
- NCT05435677
- Testing
- IcoSema, insulin icodec, semaglutide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Heart Failure
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07390110
- Testing
- Oral semaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 25,664 people
- Sponsor
- Brigham and Women's Hospital